Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05110937 · ClinicalTrials.gov registry record
Dysfunctional Myelopoiesis and Myeloid-Derived Suppressor Cells in Sepsis
A clinical trial of Sepsis and Trauma Injury, sponsored by University of Florida.
- Recruiting
- Registry status
- 450
- Enrollment target
- 1
- Study location
NCT05110937: Recruiting study of Sepsis and Trauma Injury, sponsored by University of Florida.
NCT05110937 is a study of Sepsis and Trauma Injury that is actively recruiting participants, run by University of Florida. The registered enrollment target is 450 participants, below the 6,560-participant average among 90 other Sepsis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05110937, a study of Sepsis and Trauma Injury, is actively recruiting participants, sponsored by University of Florida.
- RECRUITING
- Registry status
- 450 participants
- Enrollment target
- 1
- Study location
Study Summary
Adverse outcomes in surgical sepsis patients are secondary to dysregulated emergency myelopoiesis, and expansion of myeloid-derived suppressor cells. Here we propose to determine the underlying mechanisms behind the increased expansion of these leukocyte populations and the underlying mechanisms that drive inflammation and immune suppression.
Primary Outcome
The total number of neutrophils and early Myeloid derived suppressor cells will be measured at sepsis onset and during hospitalization and at 3 and 6 months.
Conditions Studied
Interventions
- OTHER Blood sampling
Study Locations (1)
Florida
- UF Health at Shands hospital - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2022-01-04 |
| Est. Completion | 2027-04 |
What NCT05110937 shows while recruiting
NCT05110937 is an observational study that tracks outcomes without assigning an intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, below the 6,560-participant average among 90 other Sepsis trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which Blood sampling is the first listed.
NCT05110937 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05110937 about?
NCT05110937 is a clinical study titled "Dysfunctional Myelopoiesis and Myeloid-Derived Suppressor Cells in Sepsis". Adverse outcomes in surgical sepsis patients are secondary to dysregulated emergency myelopoiesis, and expansion of myeloid-derived suppressor cells. Here we propose to determine the underlying mechanisms behind the increased expansion of these leukocyte populations and the underlying mechanisms tha...
What is the current status of trial NCT05110937?
This trial is currently recruiting. The enrollment target is 450 participants. The study started on 2022-01-04. Estimated completion is 2027-04.
What conditions does trial NCT05110937 study?
This clinical trial studies the following conditions: Sepsis, Trauma Injury.
What interventions are being tested in trial NCT05110937?
The interventions under investigation include: Blood sampling (OTHER).
Who is sponsoring clinical trial NCT05110937?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05110937 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05110937's enrollment target sits among peer trials
450 27th of 90 higher than 64 of 90 other Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The APS Phenotyping Study
RECRUITING
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Renin Angiotensin Aldosterone System In Septic Kids
RECRUITING
-
The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls
RECRUITING · NA
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI